Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...

Following this initial assessment, proof-of-concept studies are planned for patients with idiopathic Parkinson's disease. Preclinical data underscores the potential of BT-267 as the best-in-class ...

Professor Wenderlein addresses the important and interesting subject of neuroprotective and preventive measures for intervention in the pathophysiological processes of Parkinson's disease.

Idiopathic Parkinson's disease (PD) is the most common cause of parkinsonism, and dopaminergic agents provide important benefits in terms of relief of motor symptoms. By contrast, 5-10% of cases ...

Parkinson’s disease can be due to genetic or environmental factors. It can be familial, meaning it runs in families, or idiopathic, when there’s no clear cause. Most cases of Parkinson’s ...

The firm will test the activity of NEU-411 in patients with Parkinson's caused by LRRK2 mutations or whose disease is influenced by LRRK2 overactivity.

Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and ...